The Future of RH Treatment: AHA 2022 Highlights

Target Audience
This activity has been designed to address the educational needs of primary care providers, including internists, family physicians, clinical pharmacists, nurse practitioners, and PAs, as well as nephrologists, cardiologists, endocrinologists, obesity specialists, gerontologists, and other clinicians who are involved or interested in the management of patients with resistant hypertension (RH).

Program Overview
The American Heart Association 2022 Scientific Sessions was fertile ground for blockbuster studies on emerging advances in the treatment of RH. Join hypertension expert George Bakris, MD as he reviews and contextualizes key findings from clinical trial programs of first-ever novel RH agents that may soon be available.

Learning Objective
Upon completion of this activity, participants should be better able to:

Describe characteristics of novel agents that are in late-phase investigation for the treatment of RH